NO331669B1 - Organstans, beskyttelse og bevaring - Google Patents

Organstans, beskyttelse og bevaring Download PDF

Info

Publication number: NO331669B1
Authority: NO; Norway
Prior art keywords: composition according; adenosine; solution; hearts; heart
Prior art date: 1999-03-23

Application number

NO20014557A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014557D0 (no

NO20014557L (no

Inventor

Geoffrey Philip Dobson

Original Assignee

Hibernation Therapeutics Global Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-23

Filing date

2001-09-19

Publication date

2012-02-20

1999-03-23 Priority claimed from AUPP9414A external-priority patent/AUPP941499A0/en

1999-11-23 Priority claimed from AUPQ4199A external-priority patent/AUPQ419999A0/en

2001-09-19 Application filed by Hibernation Therapeutics Global Ltd filed Critical Hibernation Therapeutics Global Ltd

2001-09-19 Publication of NO20014557D0 publication Critical patent/NO20014557D0/no

2001-11-07 Publication of NO20014557L publication Critical patent/NO20014557L/no

2012-02-20 Publication of NO331669B1 publication Critical patent/NO331669B1/no

Links

210000000056 organ Anatomy 0.000 title claims abstract description 29
230000004224 protection Effects 0.000 title description 8
239000000203 mixture Substances 0.000 claims abstract description 62
239000003589 local anesthetic agent Substances 0.000 claims abstract description 17
238000000034 method Methods 0.000 claims abstract description 17
239000003379 purinergic P1 receptor agonist Substances 0.000 claims abstract description 11
229940122614 Adenosine receptor agonist Drugs 0.000 claims abstract description 10
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 110
239000002126 C01EB10 - Adenosine Substances 0.000 claims description 55
229960005305 adenosine Drugs 0.000 claims description 55
239000000243 solution Substances 0.000 claims description 55
229960004194 lidocaine Drugs 0.000 claims description 42
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical group CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 41
239000011591 potassium Substances 0.000 claims description 26
229910052700 potassium Inorganic materials 0.000 claims description 26
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 24
239000003814 drug Substances 0.000 claims description 13
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
239000003085 diluting agent Substances 0.000 claims description 12
239000002671 adjuvant Substances 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 11
229940079593 drug Drugs 0.000 claims description 11
239000003937 drug carrier Substances 0.000 claims description 10
239000000872 buffer Substances 0.000 claims description 7
239000011777 magnesium Substances 0.000 claims description 6
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
239000003416 antiarrhythmic agent Substances 0.000 claims description 5
229910052749 magnesium Inorganic materials 0.000 claims description 5
JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 claims description 4
108010023197 Streptokinase Proteins 0.000 claims description 4
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 4
229960002768 dipyridamole Drugs 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
229960002409 mepivacaine Drugs 0.000 claims description 4
INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 4
229960001807 prilocaine Drugs 0.000 claims description 4
MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 4
229960004919 procaine Drugs 0.000 claims description 4
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
229960005202 streptokinase Drugs 0.000 claims description 4
MHKFLPIBDSYTPZ-AXYPVASZSA-N (2r,3r,4r,5r)-3-amino-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-(2-phenylethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(CCC=2C=CC=CC=2)O[C@H](CO)[C@@H](O)[C@@]1(N)O MHKFLPIBDSYTPZ-AXYPVASZSA-N 0.000 claims description 3
239000008156 Ringer's lactate solution Substances 0.000 claims description 3
BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 claims description 2
VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims description 2
ZHWHMUIGIKPSJN-WOUKDFQISA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-ethyl-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(CC)O[C@H](CO)[C@@H](O)[C@H]1O ZHWHMUIGIKPSJN-WOUKDFQISA-N 0.000 claims description 2
LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 claims description 2
PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 claims description 2
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 2
229960000643 adenine Drugs 0.000 claims description 2
230000003293 cardioprotective effect Effects 0.000 claims description 2
OJEYDZBIAYMFFD-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1C[CH]CC1 OJEYDZBIAYMFFD-UHFFFAOYSA-N 0.000 claims description 2
229960003404 mexiletine Drugs 0.000 claims description 2
229960002036 phenytoin Drugs 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
MSNTZMLEKKIWJV-SDBHATRESA-N (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-2-(cyclopenten-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(C=2CCCC=2)O[C@H](CO)[C@@H](O)[C@H]1O MSNTZMLEKKIWJV-SDBHATRESA-N 0.000 claims 1
239000004036 potassium channel stimulating agent Substances 0.000 abstract description 5
239000000556 agonist Substances 0.000 abstract description 4
210000002216 heart Anatomy 0.000 description 124
241000700159 Rattus Species 0.000 description 34
239000004480 active ingredient Substances 0.000 description 27
208000028867 ischemia Diseases 0.000 description 22
230000000302 ischemic effect Effects 0.000 description 16
238000011084 recovery Methods 0.000 description 14
208000010125 myocardial infarction Diseases 0.000 description 12
230000010412 perfusion Effects 0.000 description 12
230000006378 damage Effects 0.000 description 11
239000007788 liquid Substances 0.000 description 11
239000000725 suspension Substances 0.000 description 11
230000035488 systolic blood pressure Effects 0.000 description 11
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 9
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 9
239000011575 calcium Substances 0.000 description 9
210000004351 coronary vessel Anatomy 0.000 description 9
238000001356 surgical procedure Methods 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 8
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 8
239000011734 sodium Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000036772 blood pressure Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
235000001727 glucose Nutrition 0.000 description 6
239000008103 glucose Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
230000002107 myocardial effect Effects 0.000 description 6
239000003755 preservative agent Substances 0.000 description 6
230000010410 reperfusion Effects 0.000 description 6
229920002527 Glycogen Polymers 0.000 description 5
208000010496 Heart Arrest Diseases 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
229940100084 cardioplegia solution Drugs 0.000 description 5
230000002526 effect on cardiovascular system Effects 0.000 description 5
229940096919 glycogen Drugs 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
235000015424 sodium Nutrition 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 4
108091006146 Channels Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
210000000709 aorta Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
239000006071 cream Substances 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000002503 metabolic effect Effects 0.000 description 4
230000036284 oxygen consumption Effects 0.000 description 4
229950007002 phosphocreatine Drugs 0.000 description 4
229960002310 pinacidil Drugs 0.000 description 4
238000011027 product recovery Methods 0.000 description 4
230000033764 rhythmic process Effects 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
102000004257 Potassium Channel Human genes 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000017531 blood circulation Effects 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
235000011148 calcium chloride Nutrition 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
230000006872 improvement Effects 0.000 description 3
229960005015 local anesthetics Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000006072 paste Substances 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
108020001213 potassium channel Proteins 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
239000012089 stop solution Substances 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
CHMUHOFITZIING-XNIJJKJLSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-cyclohexyl-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(C2CCCCC2)O[C@H](CO)[C@@H](O)[C@H]1O CHMUHOFITZIING-XNIJJKJLSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
206010011086 Coronary artery occlusion Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229940123457 Free radical scavenger Drugs 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
102000016924 KATP Channels Human genes 0.000 description 2
108010053914 KATP Channels Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241001494479 Pecora Species 0.000 description 2
229940127315 Potassium Channel Openers Drugs 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010047281 Ventricular arrhythmia Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000036982 action potential Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000003288 anthiarrhythmic effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
230000003683 cardiac damage Effects 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
230000001101 cardioplegic effect Effects 0.000 description 2
230000005961 cardioprotection Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000000446 fuel Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
229960004580 glibenclamide Drugs 0.000 description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
230000001788 irregular Effects 0.000 description 2
208000037906 ischaemic injury Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000028161 membrane depolarization Effects 0.000 description 2
230000007102 metabolic function Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
239000002687 nonaqueous vehicle Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
210000003463 organelle Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
238000005086 pumping Methods 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000004904 shortening Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000003195 sodium channel blocking agent Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
KAWIOCMUARENDQ-UHFFFAOYSA-N 2-(4-chlorophenyl)sulfanyl-n-(4-pyridin-2-yl-1,3-thiazol-2-yl)acetamide Chemical compound C1=CC(Cl)=CC=C1SCC(=O)NC1=NC(C=2N=CC=CC=2)=CS1 KAWIOCMUARENDQ-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
102000009346 Adenosine receptors Human genes 0.000 description 1
108050000203 Adenosine receptors Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000272878 Apodiformes Species 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
206010069729 Collateral circulation Diseases 0.000 description 1
208000002330 Congenital Heart Defects Diseases 0.000 description 1
208000034657 Convalescence Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010068370 Glutens Proteins 0.000 description 1
244000148687 Glycosmis pentaphylla Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000006391 Ion Pumps Human genes 0.000 description 1
108010083687 Ion Pumps Proteins 0.000 description 1
239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108091005975 Myofilaments Proteins 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
244000235659 Rubus idaeus Species 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000270666 Testudines Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940023476 agar Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000002583 angiography Methods 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
231100000659 animal toxin Toxicity 0.000 description 1
230000001466 anti-adreneric effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
238000003287 bathing Methods 0.000 description 1
238000010009 beating Methods 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
229940092782 bentonite Drugs 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002715 bioenergetic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
230000001964 calcium overload Effects 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960003260 chlorhexidine Drugs 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
208000028831 congenital heart disease Diseases 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
235000021312 gluten Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002806 hypometabolic effect Effects 0.000 description 1
229960003943 hypromellose Drugs 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000004941 influx Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
210000003632 microfilament Anatomy 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229960002497 nicorandil Drugs 0.000 description 1
LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
239000002840 nitric oxide donor Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000004681 ovum Anatomy 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
229940096826 phenylmercuric acetate Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000003450 potassium channel blocker Substances 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
230000036316 preload Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
210000004706 scrotum Anatomy 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229940001607 sodium bisulfite Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
229950010357 tetrodotoxin Drugs 0.000 description 1
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
229940093612 zein Drugs 0.000 description 1
239000005019 zein Substances 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Environmental Sciences (AREA)
Wood Science & Technology (AREA)
Dentistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Biophysics (AREA)
Physiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Packages (AREA)
Processing Of Solid Wastes (AREA)
Materials For Medical Uses (AREA)
Saccharide Compounds (AREA)

NO20014557A 1999-03-23 2001-09-19 Organstans, beskyttelse og bevaring NO331669B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AUPP9414A AUPP941499A0 (en)	1999-03-23	1999-03-23	Organ arrest, protection and preservation
AUPQ4199A AUPQ419999A0 (en)	1999-11-23	1999-11-23	Organ arrest, protection and preservation
PCT/AU2000/000226 WO2000056145A1 (en)	1999-03-23	2000-03-22	Organ arrest, protection and preservation

Publications (3)

Publication Number	Publication Date
NO20014557D0 NO20014557D0 (no)	2001-09-19
NO20014557L NO20014557L (no)	2001-11-07
NO331669B1 true NO331669B1 (no)	2012-02-20

Family

ID=25646014

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20014557A NO331669B1 (no)	1999-03-23	2001-09-19	Organstans, beskyttelse og bevaring
NO20110807A NO20110807L (no)	1999-03-23	2011-06-03	Anvendelse av kaliumkanalapner, kaliumkanalagonist og adenosinreseptoragonist, samt lokalbedovende middel for stansing og/eller beskyttelse av et organ eller vev

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20110807A NO20110807L (no)	1999-03-23	2011-06-03	Anvendelse av kaliumkanalapner, kaliumkanalagonist og adenosinreseptoragonist, samt lokalbedovende middel for stansing og/eller beskyttelse av et organ eller vev

Country Status (17)

Country	Link
US (7)	US6955814B1 (de)
EP (3)	EP2359688B1 (de)
JP (1)	JP4949558B2 (de)
KR (1)	KR20020001797A (de)
CN (1)	CN1344135A (de)
AT (1)	ATE361667T1 (de)
BR (1)	BR0010653A (de)
CA (1)	CA2364687C (de)
DE (1)	DE60034778T2 (de)
ES (1)	ES2287001T3 (de)
IL (1)	IL145552A0 (de)
MX (1)	MXPA01009552A (de)
NO (2)	NO331669B1 (de)
NZ (1)	NZ514515A (de)
PL (1)	PL351484A1 (de)
TR (1)	TR200103235T2 (de)
WO (1)	WO2000056145A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ514515A (en)	1999-03-23	2003-11-28	Global Cardiac Solutions Pty L	Organ arrest, protection and preservation using a potassium channel operator and/or adenosine receptor and a local anaesthetic
US7011854B2 (en)	2002-02-04	2006-03-14	Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda	Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
AUPS312602A0 (en) *	2002-06-21	2002-07-18	James Cook University	Organ arrest, protection, preservation and recovery
US20040170950A1 (en) *	2002-09-12	2004-09-02	Prien Samuel D.	Organ preservation apparatus and methods
AU2003291847B2 (en) *	2002-12-23	2010-12-02	Hibernation Therapeutics, A Kf Llc	Organ preconditioning, arrest, protection, preservation and recovery
CA2551169A1 (en) *	2002-12-23	2004-07-08	Global Cardiac Solutions Pty Ltd	Organ preconditioning, arrest, protection, preservation and recovery
CN101453984A (zh) *	2006-03-31	2009-06-10	艾登欧比公司	使用腺苷和肌苷组合用于诊断和治疗的组合物、方法和试剂盒
AU2006345361B2 (en) *	2006-05-29	2014-04-10	Hibernation Therapeutics, A Kf Llc	Improved tissue maintenance
CN104107431A (zh) *	2006-05-29	2014-10-22	低温药理有限公司	改善的组织维持
US7811549B2 (en) *	2006-07-05	2010-10-12	Adenobio N.V.	Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
CA2692256C (en) *	2006-07-25	2017-01-10	Hibernation Therapeutics Limited	Trauma therapy
EP2173353B1 (de)	2007-03-02	2015-05-06	Hibernation Therapeutics, a KF LLC	Zusammensetzung mit Adenosin und Lignocain
US20080269109A1 (en) *	2007-04-30	2008-10-30	Becker Lance B	System and method of resuscitation of a mammal
SG185322A1 (en) *	2007-07-25	2012-11-29	Hibernation Therapeutics Ltd	Improved organ protection, preservation and recovery
DE102007035642A1 (de) *	2007-07-30	2009-02-12	Grietje Beck	Substanzen zur Protektion von Zellen und Geweben gegen Schädigung durch ungünstige Bedingungen
WO2009092516A2 (en) *	2008-01-22	2009-07-30	Adenobio N.V.	Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
US20120046354A1 (en) *	2010-08-18	2012-02-23	Ehrenpreis Eli D	Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders
US9163044B2 (en)	2011-04-19	2015-10-20	Alfama, Inc.	Carbon monoxide releasing molecules and uses thereof
ES2628634T3 (es)	2011-07-21	2017-08-03	Alfama, Inc.	Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
WO2014063134A1 (en)	2012-10-19	2014-04-24	New York University	Methods for inhibiting osteolysis
BR112016000809A2 (pt)	2013-07-17	2017-08-22	Hibernation Therapeuitics A Kf Llc	Método para tratar infecção, sepsia e lesão
JP2013234200A (ja) *	2013-08-19	2013-11-21	Hibernation Therapeutics Ltd	組織維持の改善
US10092591B2 (en)	2014-02-27	2018-10-09	University Of Alaska Fairbanks	Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
CN103893205B (zh) *	2014-04-15	2016-03-09	青岛大学附属医院	一种包含利多卡因和腺苷的心脏停搏液及其制备方法
CA2947711A1 (en) *	2014-05-01	2015-11-05	Catherine E. Berry	A modified single dose, microplegic approach to cardioplegia for the adult heart
US9501418B2 (en) *	2014-06-26	2016-11-22	HGST Netherlands B.V.	Invalidation data area for cache
US9913903B2 (en) *	2015-08-06	2018-03-13	Grifols Worldwide Operations Limited	Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
CN109769797B (zh) *	2017-11-13	2024-09-10	合肥华琪生物工程有限公司	一种器官保存液
US12471592B2 (en)	2021-08-18	2025-11-18	Reelabs Private Limited	Cytoprotective compositions for short-term cells storage and transportation without cryopreservation and deep freezing

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU878297A1 (ru)	1978-05-03	1981-11-07	Научно-Исследовательский Институт Трансплантологии И Искусственных Органов	Состав дл сохранени жизнеспособности оперируемого сердца
US4798824A (en)	1985-10-03	1989-01-17	Wisconsin Alumni Research Foundation	Perfusate for the preservation of organs
US5006512A (en)	1987-10-02	1991-04-09	Tsuyoshi Ohnishi	Therapeutic usages of inhibitors for a potassium efflux channel
US5256770A (en) *	1990-04-09	1993-10-26	Schering Ag	Oxidation resistant thrombomodulin analogs
DE3926287A1 (de) *	1989-08-09	1991-02-21	Bernhard Clasbrummel	Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5145771A (en) *	1990-04-12	1992-09-08	The University Of North Carolina At Chapel Hill	Rinse solution for organs and tissues
US5206222A (en)	1991-05-22	1993-04-27	Vanderbilt University	Methods for the reduction of myocardial reperfusion injury
CN1057192A (zh)	1991-06-30	1991-12-25	汪庆富	风油精聚胺酯海绵的制备工艺
US5407793A (en)	1991-10-18	1995-04-18	University Of Pittsburgh Of The Commonwealth System Of Higher Education	An aqueous heart preservation and cardioplegia solution
RU2025973C1 (ru) *	1992-02-10	1995-01-09	Научно-производственное предприятие "Биофарм"	Раствор для консервации живых органов
US5370989A (en)	1992-04-03	1994-12-06	The Trustees Of Columbia University In The City Of New York	Solution for prolonged organ preservation
US5405742A (en) *	1993-07-16	1995-04-11	Cyromedical Sciences, Inc.	Solutions for tissue preservation and bloodless surgery and methods using same
US5679706A (en) *	1994-09-30	1997-10-21	Bristol-Myers Squibb Company	Combination of a potassium channel activator and an antiarrhythmic agent
US5554497A (en) *	1994-12-12	1996-09-10	Charlotte-Mecklenburg Hospital Authority	Cardioplegic solution for arresting an organ
US5656420A (en) *	1995-02-24	1997-08-12	University Of Kentucky Research Foundation	Method for employing the delta opioid dadle to extend tissue survival time during ischemia
JP3875295B2 (ja) *	1995-11-30	2007-01-31	功竹内	心筋保護液
EP1006798A4 (de)	1996-09-05	2003-03-05	Massachusetts Inst Technology	Zusammensetzungen und verfahren zur behandlung neurologischer störungen und neurodegenerativer erkrankungen
IT1297886B1 (it) *	1997-02-28	1999-12-20	Carmine Antropoli	Nifedipina per uso topico
EP1014995A4 (de)	1997-06-18	2005-02-16	Aderis Pharmaceuticals Inc	Zusammensetzungen und verfahren zur verhütung von restenosis nach wiedergefässbildung
CN1057192C (zh)	1997-09-10	2000-10-11	上海长征医院	一种配制多器官保存液的方法
US6011017A (en)	1998-04-15	2000-01-04	Cypros Pharmaceutical Corp.	Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
KR100762018B1 (ko)	1998-07-16	2007-10-04	메모리얼 슬로안-케터링 캔서 센터	오피오이드 진통제 및 엔엠디에이 길항제를 함유하는 국소조성물
KR100269540B1 (ko)	1998-08-28	2000-10-16	윤종용	웨이퍼 상태에서의 칩 스케일 패키지 제조 방법
KR100683603B1 (ko)	1998-10-23	2007-02-20	폴리힐 엘티디.	창상 치유용 미소구 조성물
US6358208B1 (en)	1998-11-21	2002-03-19	Philipp Lang	Assessment of cardiovascular performance using ultrasound methods and devices that interrogate interstitial fluid
NZ514515A (en) *	1999-03-23	2003-11-28	Global Cardiac Solutions Pty L	Organ arrest, protection and preservation using a potassium channel operator and/or adenosine receptor and a local anaesthetic
US6586413B2 (en) *	1999-11-05	2003-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
WO2001054679A2 (en)	2000-01-27	2001-08-02	Children's Hospital Research Foundation	Transdermal composition containing an anesthetic and a vasodilator agent
JP2001261575A (ja)	2000-03-13	2001-09-26	General Hospital Corp	血管収縮を調節する方法とその組成物
US6569615B1 (en)	2000-04-10	2003-05-27	The United States Of America As Represented By The Department Of Veteran's Affairs	Composition and methods for tissue preservation
KR20030060771A (ko)	2000-04-28	2003-07-16	메모리얼 슬로안-케터링 캔서 센터	국소용 마취제/아편양약물 제제 및 이들의 용도
WO2002026140A1 (en)	2000-09-26	2002-04-04	Medtronic, Inc.	Medical method and system for directing blood flow
GB0028414D0 (en)	2000-11-22	2001-01-03	Univ Leeds	Flush preservation solution
JP2005532260A (ja)	2002-01-29	2005-10-27	コグネティックス・インコーポレイテッド	器官保護剤としてのカッパ−ｐｖｉｉａ−関連コノトキシン
ATE418991T1 (de)	2002-04-18	2009-01-15	Cv Therapeutics Inc	Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
AUPS312602A0 (en)	2002-06-21	2002-07-18	James Cook University	Organ arrest, protection, preservation and recovery
US20040229780A1 (en) *	2002-09-20	2004-11-18	Olivera Baldomero M.	KappaM-conopeptides as organ protectants
US6921633B2 (en)	2002-11-18	2005-07-26	Biolife Solutions Incorporated	Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
US20040167226A1 (en)	2002-12-16	2004-08-26	Serafini Tito A.	Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
GB2436255B (en)	2002-12-23	2007-11-28	Global Cardiac Solutions Pty L	Organ preconditioning, arrest, protection, preservation and recovery
CA2551169A1 (en)	2002-12-23	2004-07-08	Global Cardiac Solutions Pty Ltd	Organ preconditioning, arrest, protection, preservation and recovery
US6992075B2 (en)	2003-04-04	2006-01-31	Barr Laboratories, Inc.	C(14) estrogenic compounds
EP1628649A4 (de)	2003-06-02	2010-06-02	Samaritan Pharmaceuticals Inc	Neuroprotektive benzoat- und benzamid-verbindungen
US7049309B2 (en) *	2003-10-14	2006-05-23	Bristol-Myers Squibb Company	3-Thia-4-arylquinolin-2-one potassium channel modulators
JP2008525468A (ja)	2004-12-22	2008-07-17	エモリー・ユニバーシティ	ポストコンディショニング臓器保護作用を増強する治療補助薬
WO2007030198A2 (en)	2005-07-11	2007-03-15	Human Biosystems	Improved methods and solutions for storing donor organs
AU2006345361B2 (en)	2006-05-29	2014-04-10	Hibernation Therapeutics, A Kf Llc	Improved tissue maintenance
CA2692256C (en)	2006-07-25	2017-01-10	Hibernation Therapeutics Limited	Trauma therapy
EP2173353B1 (de)	2007-03-02	2015-05-06	Hibernation Therapeutics, a KF LLC	Zusammensetzung mit Adenosin und Lignocain
CN100423638C (zh)	2007-03-22	2008-10-08	南京吉脉生物技术有限公司	一种器官保存液及其制备方法
SG185322A1 (en)	2007-07-25	2012-11-29	Hibernation Therapeutics Ltd	Improved organ protection, preservation and recovery

2000
- 2000-03-22 NZ NZ514515A patent/NZ514515A/en not_active IP Right Cessation
- 2000-03-22 CA CA2364687A patent/CA2364687C/en not_active Expired - Fee Related
- 2000-03-22 WO PCT/AU2000/000226 patent/WO2000056145A1/en not_active Ceased
- 2000-03-22 KR KR1020017012071A patent/KR20020001797A/ko not_active Withdrawn
- 2000-03-22 BR BR0010653-4A patent/BR0010653A/pt not_active Application Discontinuation
- 2000-03-22 ES ES00910414T patent/ES2287001T3/es not_active Expired - Lifetime
- 2000-03-22 JP JP2000606063A patent/JP4949558B2/ja not_active Expired - Fee Related
- 2000-03-22 CN CN00805408A patent/CN1344135A/zh active Pending
- 2000-03-22 EP EP10181888.8A patent/EP2359688B1/de not_active Expired - Lifetime
- 2000-03-22 IL IL14555200A patent/IL145552A0/xx unknown
- 2000-03-22 US US09/937,181 patent/US6955814B1/en not_active Expired - Lifetime
- 2000-03-22 PL PL00351484A patent/PL351484A1/xx not_active Application Discontinuation
- 2000-03-22 AT AT00910414T patent/ATE361667T1/de not_active IP Right Cessation
- 2000-03-22 EP EP06077320A patent/EP1790223A1/de not_active Withdrawn
- 2000-03-22 DE DE60034778T patent/DE60034778T2/de not_active Expired - Lifetime
- 2000-03-22 MX MXPA01009552A patent/MXPA01009552A/es unknown
- 2000-03-22 TR TR2001/03235T patent/TR200103235T2/xx unknown
- 2000-03-22 EP EP00910414A patent/EP1168912B1/de not_active Expired - Lifetime
2001
- 2001-09-19 NO NO20014557A patent/NO331669B1/no not_active IP Right Cessation
2005
- 2005-02-01 US US11/046,866 patent/US7223413B2/en not_active Expired - Fee Related
2007
- 2007-04-24 US US11/790,216 patent/US20070270372A1/en not_active Abandoned
2009
- 2009-08-13 US US12/541,000 patent/US7749522B2/en not_active Expired - Fee Related
2010
- 2010-05-27 US US12/788,864 patent/US20100298254A1/en not_active Abandoned
2011
- 2011-06-03 NO NO20110807A patent/NO20110807L/no not_active Application Discontinuation
2013
- 2013-03-05 US US13/786,041 patent/US9320753B2/en not_active Expired - Fee Related
2016
- 2016-03-18 US US15/074,471 patent/US20160263141A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1168912B1 (de)	2007-05-09
DE60034778D1 (de)	2007-06-21
US20050171050A1 (en)	2005-08-04
KR20020001797A (ko)	2002-01-09
JP2002539224A (ja)	2002-11-19
EP2359688A1 (de)	2011-08-24
JP4949558B2 (ja)	2012-06-13
HK1161035A1 (en)	2012-08-24
NO20014557D0 (no)	2001-09-19
ATE361667T1 (de)	2007-06-15
US20090298789A1 (en)	2009-12-03
IL145552A0 (en)	2002-06-30
US7223413B2 (en)	2007-05-29
US6955814B1 (en)	2005-10-18
WO2000056145A1 (en)	2000-09-28
US7749522B2 (en)	2010-07-06
US20130184231A1 (en)	2013-07-18
DE60034778T2 (de)	2008-01-31
CA2364687A1 (en)	2000-09-28
EP1168912A1 (de)	2002-01-09
NO20110807L (no)	2001-11-07
PL351484A1 (en)	2003-04-22
CN1344135A (zh)	2002-04-10
CA2364687C (en)	2014-11-18
NO20014557L (no)	2001-11-07
US20070270372A1 (en)	2007-11-22
MXPA01009552A (es)	2003-08-19
BR0010653A (pt)	2002-02-05
EP1168912A4 (de)	2002-07-31
EP1790223A1 (de)	2007-05-30
EP2359688B1 (de)	2015-05-27
NZ514515A (en)	2003-11-28
TR200103235T2 (tr)	2002-01-21
US20100298254A1 (en)	2010-11-25
US9320753B2 (en)	2016-04-26
ES2287001T3 (es)	2007-12-16
US20160263141A1 (en)	2016-09-15

Legal Events

Date	Code	Title	Description
2015-01-19	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: HIBERNATION THERAPEUTICS, US
2017-10-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO331669B1 (no)	2012-02-20	Organstans, beskyttelse og bevaring
EP2139316B1 (de)	2015-03-18	Traumatherapie
Pourcyrous et al.	1993	Brain superoxide anion generation in asphyxiated piglets and the effect of indomethacin at therapeutic dose
AU2003232526B2 (en)	2010-07-01	Organ arrest, protection, preservation and recovery
US20120094268A1 (en)	2012-04-19	Tissue maintenance
Hudspeth et al.	1994	Adenosine in blood cardioplegia prevents postischemic dysfunction in ischemically injured hearts
AU769131B2 (en)	2004-01-15	Organ arrest, protection and preservation
CA3088213A1 (en)	2019-08-08	Compositions and devices for systemic delivery of uridine
HK1161035B (en)	2016-04-29	Organ arrest, protection and preservation
US20030166605A1 (en)	2003-09-04	Method of minimizing damage to heart tissue during cardiac surgery and cardiac transplantation
CN114796217B (zh)	2025-01-24	一种含有西洛他唑的组合物在制备治疗脑血管病药物中的应用
ZA200107644B (en)	2002-09-17	Organ arrest, protection and preservation.
JP2013234200A (ja)	2013-11-21	組織維持の改善
HK1190877A (en)	2014-07-18	Improved tissue maintenance
HK1172794A (en)	2013-05-03	Improved tissue maintenance
HK1193048A (en)	2014-09-12	Trauma therapy